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EPIDEMIOLOGY AND PREVENTION
Changing Antiretroviral Eligibility Criteria: Impact on
the Number and Proportion of Adults Requiring
Treatment in Swaziland
Naomi N. Bock, MD, MS,* Ruth C. Emerson, MPH,† Jason B. Reed, MD, MPH,*
Rejoice Nkambule, MPH,‡ Deborah J. Donnell, PhD,† George T. Bicego, PhD,*
Velephi Okello, MBChB, MPH,‡ Neena M. Philip, MPH,§ Peter D. Ehrenkranz, MD, MPH,k
Yen T. Duong, PhD,* Janet S. Moore, PhD,* and Jessica E. Justman, MD§
Objective: Early initiation of antiretroviral treatment (ART) at CD4+
cell count$500 cells per microliter reduces morbidity and mortality in
HIV-infected adults. We determined the proportion of HIV-infected
people with high viral load (VL) for whom transmission prevention
would be an additional benefit of early treatment.
Design: A randomly selected subset of a nationally representative
sample of HIV-infected adults in Swaziland in 2012.
Methods: Eight to 12 months after a national survey to
determine adult HIV prevalence, 1067 of 5802 individuals
identified as HIV-infected were asked to participate in a follow-
up cross-sectional assessment. CD4+ cell enumeration, VL
measurements, and ART status were obtained to estimate the
proportion of currently untreated adults and of the entire HIV-
infected population with high VL ($1000 copies/mL) whose
treatment under a test-and-treat or VL threshold eligibility
strategy would reduce HIV transmission.
Results: Of the 927 (87% of 1067) participants enrolled, 466 (50%)
reported no ART use. Among them, 424 (91%) had VL $1000
copies per milliliter; of these, 148 (35%) were eligible for ART at the
then existing CD4+ count threshold of ,350 cells per microliter; an
additional 107 (25%) were eligible with expanded CD4+ criterion
of ,500 cells per microliter; and 169 (40%) remained ART
ineligible. Thus, 36% of the 466 currently untreated and 18% of
the total 927 had high VL yet remained ART ineligible under
a CD4+ criterion of ,500 cells per microliter.
Conclusions: A test-and-treat or VL threshold for treatment
eligibility is necessary to maximize the HIV transmission prevention
benefits of ART.
Key Words: HIV, antiretroviral treatment, HIV treatment eligibility,
CD4+ count, viral load, Swaziland
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INTRODUCTION
Well into the fourth decade of the global HIV
epidemic, an estimated 35 million people are living with
HIV. Sub-Saharan Africa accounts for approximately 24.7
million prevalent infections and more than two-third of new
annual HIV infections worldwide.1 Although the numbers
remain daunting, the high prevalence partially reflects
reduced morbidity and mortality through increasing access
to antiretroviral treatment (ART). Recent studies have
documented that morbidity and mortality can be further
reduced by early initiation of ART in asymptomatic persons
with high CD4 counts.2,3 In response, the World Health
Organization has announced that new treatment guidelines
recommending the treatment for all regardless of CD4+ cell
count will be forthcoming.4
In addition to the benefits to individual health, in 2011,
a randomized controlled trial found 96% reduction in HIV
transmission among discordant heterosexual couples, where
the HIV-infected partner was started on ART at CD4+ count
between 350 and 550 cells per microliter compared with
deferral of ART until CD4+ cell count fell to below 250 cells
per microliter, establishing the efficacy of treatment as
prevention.5 Possibilities of and barriers to expanding HIV
treatment for prevention, either by treating those with high
viral load (VL) despite high CD4+ cell counts or by treating
all HIV-infected individuals irrespective of CD4+ cell count
and VL, have been widely discussed.6–8
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A major barrier to expanding ART coverage is the
complex continuum of HIV care, which Gardner et al9 refer
to as the “spectrum of engagement in HIV care.” Each of 6
defined steps along the continuum—HIV diagnosis by
testing, linkage to care, retention in care, starting appro-
priate ART, adherence with ART, and achieving viral
suppression—have been demonstrated as programmatic
vulnerabilities, where individual patients can and do
disengage, ultimately resulting in morbidity and mortality
and also uncontrolled VL and increased transmission risk.
Initial cost for treatment expansion, despite the long-term
cost savings, is another barrier.10
Given the risks of overburdening already stretched
infrastructures, and also the additional costs, it is helpful to
quantify the degree to which a national ART program would
have to expand if it were to include either all HIV-infected
adults or those with high VL who are at the greatest risk of
transmitting HIV but not “eligible” for treatment based on
CD4+ cell count. In this study, we use data from the
nationally representative Swaziland HIV Incidence Mea-
surement Survey (SHIMS) to examine the potential pre-
vention impact of current treatment guidelines in Swaziland,
a country with one of the highest HIV incidence and
prevalence rates in the world.11,12
METHODS
Sampling Scheme and Eligibility Criteria
A detailed description of the SHIMS sampling scheme
has been previously described.12 Briefly, a 2-stage cluster
sample design selected census or enumeration areas and then
households within each enumeration area. Adult household
members who agreed to participate underwent HIV testing and
those who were HIV-negative were offered enrollment in
a seroincidence cohort. Those who were HIV-infected were
counseled about the benefits of HIV care and treatment
services, provided a referral to facilitate their linkage to those
services, and asked for consent to be contacted for future
research. A subset of participants who were identified as HIV-
infected at baseline and who gave consent to be contacted for
future research was randomly selected to participate in
a follow-up household visit 8–12 months after their initial visit.
Study Procedures
The selected HIV-infected individuals who were located
underwent verification of their participation in the earlier
survey and were asked to participate in a follow-up cross-
sectional assessment. Those who agreed provided written
informed consent and then underwent an interviewer-
administered survey regarding medical care including current
ART use. When available, participants’ medical booklet
records of ART initiation ascertained ART use at baseline
and follow-up. When medical booklets were unavailable, this
ART information was based on self-report. Counseling about
the benefits of HIV care and treatment services, and informa-
tion on how to link to them was provided to all participants.
Approximately 10 mL of blood was obtained by venipuncture.
Laboratory Methods
Whole blood samples were transported in ethylenedia-
minetetraacetic acid tubes (Greiner Bio One, Frickenhausen,
Germany) in cooler boxes to the National Reference Labo-
ratory in Mbabane within 24 hours of collection.
CD4+ cell enumeration was determined using the
Becton Dickinson FACSCalibur automated flow cytometry
system according to the manufacturer’s instructions. Quality
assurance testing was performed on 5% of the whole blood
samples. VL quantification was performed using undiluted
plasma on the COBAS, AmpliPrep/COBAS, TaqMan,
System platform and the COBAS, AmpliPrep/COBAS,
TaqMan, and HIV-1 Test (Roche Diagnostics, Indianapolis,
IN) version 2.0 assay according to the manufacturer’s
instructions; the limit of detection for the assay was 20
copies per milliliter.
Those participants who agreed to receive their CD4+
count results received a paper copy of the results within 28
days. The study staff counseled about the benefits of HIV care
services and provided information to help those not in care
link to these services. They encouraged participants to share
the CD4+ test results with their health care provider, noting
that it would assist their provider in making decisions about
starting treatment. They also counseled participants about the
importance of HIV testing of partners.
Data Analyses
CD4+ cell enumeration, VL measurements, and ART
treatment status of participants were used to determine the
additional number and proportion of untreated adults and of
the entire estimated HIV-infected adult population who
would be eligible for ART when the then prevailing
treatment eligibility criterion of CD4+ cell count , 350
cells per microliter was expanded to include those between
350 and 499 cells per microliter. We also calculated the
number and proportion of those with high VL (HIV-1 RNA
VL .1000 copies/mL) who remained ART ineligible with
the expanded criterion of CD4+ cell count ,500 cells per
microliter.13 Finally we estimated the remaining number
and proportion who would be included in a test-and-treat
strategy. By estimating the size of the adult HIV-infected
population in Swaziland, we converted the proportions to
absolute numbers of persons potentially added to
treatment programs. We also assessed demographic and
health seeking behavior variables associated with being on
ART (for those eligible) and having suppressed VL (for
those on ART).
Statistical Methods
Survey weights were applied to the data to account for
differential probability of selection by the initial cluster
sampling procedure and nonresponse rates across sex, age,
and geography during both initial sampling procedure and
follow-up assessment of selected HIV-infected individuals.
Weighted estimates were scaled to the size of the SHIMS
subset of HIV-infected individuals who underwent the CD4+
assessment. Throughout, reports of number and proportions
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of participants are based on these scaled weighted estimates,
and thus do not always add up to 100%. When available,
participants’ medical booklet records of ART initiation
ascertained ART use at baseline and follow-up. Unadjusted
and adjusted odds ratios (OR) and 95% confidence intervals
(CI) were calculated to describe associations from logistic
regression models, using binary outcomes for the 2 depen-
dent variables of interest at follow-up, (1) ART use (yes/no)
and (2) viral suppression (yes/no), defined as ,1000 copies
per milliliter. Analyses were performed using Stata (Stata-
Corp. 2013, Stata Statistical Software: Release 13; Stata-
Corp LP, College Station, TX).
Size Estimation of HIV-Infected
Adult Population
The total population of Swaziland is projected to be
1.268 million, with near equal proportion male and female
(49.4% versus 50.6%).14 From the Swaziland 2007 Demo-
graphic and Health Survey, the proportion of adult men and
women (defined as aged 15 years and older) was 53.8% and
58.4%, respectively, thus 711,348 persons.15 Applying the
SHIMS HIV prevalence estimate of 24% of adult males and
39% of adult females12 yields 226,262 adults estimated to be
living with HIV.
Ethical Considerations
All study participants provided written informed con-
sent before the collection of data and blood samples. Ethical
approval was obtained from the Swaziland Scientific and
Ethics Committee, Columbia University Institutional Review
Board (IRB), and the US Centers for Disease Control and
Prevention IRB before initiation of field work.
RESULTS
Participants
Of 5802 participants identified as HIV-infected at
SHIMS baseline 8–12 months earlier, 1067 (18%) were
randomly selected for this follow-up study; 138 of the 1067
(13%) either could not be located or refused to participate, and
3 (0.3%) did not have CD4+ enumeration results available.
From February to May 2012, 927 participants (87% of those
selected for participation) were enrolled, interviewed, and
underwent CD4+ cell enumeration and VL assessment. Of
these 927, 65% were women, 69% lived in rural areas, 57%
reported being married or partner cohabitation, 50% were on
ART, and 71% were aware of their HIV-infected status at the
time of the baseline survey 8–12 months earlier (Table 1).
Distribution of CD4+ Cell Count and ART
Eligibility Among 466 Participants Not on ART
Eight to 12 months after the SHIMS baseline survey,
about one-third (158 of 466, or 34%) had CD4+
count ,350 cells per microliter and were eligible for
ART by national CD4 criteria at the time of the survey;
an additional 110 (24%) had CD4+ count between 350 and
499 cells per microliter and were eligible for ART by new
initiation criteria adopted by Swaziland in the summer of
2014 (Table 2). Thus, expanding eligibility criteria from
CD4+ count ,350 to ,500 cells per microliter added 12%
of the adult HIV-infected population (110 of the sampled
927) to those eligible. With the estimate of 226,262 HIV-
infected adults nationally, 26,849 more adults became
treatment eligible with the higher CD4+ cell count criteria.
By 2013 WHO guidelines, 43% of those not on ART (198
TABLE 1. Demographics and Characteristics of 927 Adults
Sampled for CD4+ Cell Count and Viral Load Stratified by the
Use of Antiretroviral Treatment (ART)*








Total 466 (50) 461 (50) 927
Sex
Female 303 (50) 301 (50) 604
Male 163 (51) 160 (50) 323
Age
18–24 122 (72) 47 (28) 169
25–29 122 (61) 78 (39) 200
30–34 90 (47) 102 (53) 192
35–39 69 (41) 98 (59) 168
40–44 42 (36) 73 (64) 115
45–49 21 (25) 63 (75) 84
HIV status awareness at
baseline
Unaware 231 (85) 40 (15) 271
Aware 235 (36) 421 (64) 656
Marital/cohabitation status
Married or cohabitating 246 (47) 280 (53) 526
Not married or
cohabitating
217 (55) 176 (45) 393
Missing response 3 (39) 5 (61) 8
Education
Did not attend 43 (50) 43 (50) 86
Primary 160 (46) 187 (54) 347
Secondary 220 (53) 197 (47) 416
Tertiary 40 (57) 30 (43) 71
Employment
Employed (any form) 202 (50) 201 (50) 403
Unemployed (including
retired/disabled)
259 (50) 257 (50) 516
Residence
Rural 310 (48) 330 (52) 640
Urban 156 (54) 131 (46) 287
Region
Hhohho 133 (55) 111 (45) 244
Lubombo 79 (49) 82 (51) 161
Manzini 185 (55) 150 (45) 335
Shiselweni 69 (37) 119 (63) 188
*Survey weighted by age, sex, and residence; numbers may not add up to 100% due
to rounding.
†Follow-up occurred 8–12 months after baseline survey.
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of 466) remain ineligible due to a CD4+ cell count of $500
cells per microliter.
Distribution of VL, CD4+ Cell Count, and
ART Eligibility
In terms of VL, 91% (424 of 466) participants not on
ART had a VL $1000 copies per milliliter (Table 2). Among
these 40% (169 of 424) had a CD4+ count $500 cells per
microliter and thus would remain ART ineligible with a CD4+
threshold of ,500 cells per microliter despite having a high
VL 8–12 months after documented HIV-infected status.
These 169 individuals represent 18% of the total 927 HIV-
positive participants in the population. With the estimated
226,262 HIV-infected adults nationally, 40,727 more adults
would become treatment eligible if a VL threshold of $1000
copies per milliliter was added to CD4+ count criteria of
,500 cells per microliter. A test-and-treat approach would
add the remaining 3% (28 of 927) of persons, those with
CD4+ count $500 cells per microliter and VL ,1000 copies
per milliliter, or 6788 adults.
Predictors of Being on ART at Follow-up 8–12
Months After SHIMS Baseline Survey Among
Those Eligible by CD4+ Threshold of ,350
Cells Per Microliter at Follow-up
Approximately one-fourth (158 of 619, or 26%) of
participants eligible for ART based on CD4+ count threshold of
,350 cells per microliter reported not being on treatment at the
time of the follow-up survey. In multivariate analysis,
participants on treatment, compared with those eligible but
not on treatment, were more likely to be older than 44 years of
age [adjusted odds ratio (aOR): 15.28; 95% CI: 3.77 to 62.01]
and to have already been aware of their HIV infection before
the SHIMS baseline survey (aOR: 10.62, CI: 6.53 to 17.25)
(Table 3). Sex, urban versus rural residence, marital status,
education level, region, and employment status were not
associated with ART treatment (data not shown). At follow-
up, almost half (72/158 or 46%) of those eligible but not on
treatment reported never having visited a health facility for
HIV-related medical care since diagnosis.
TABLE 2. Distribution of Viral Load (VL) by CD4+ Cell Count
Strata Among 466 HIV-Positive Individuals Not on ART*
VL Copies/mL
CD4+ Count Category
Total0–199 200–349 350–499 ‡500
0–999 4 6 4 28 42 (9%)
1000–9999 2 7 21 61 91 (20%)
10,000–99,999 33 40 66 90 229 (49%)
100,000+ 28 38 20 18 104 (22%)
Total 66 (14%) 92 (20%) 110 (24%) 198 (42%) 466 (100%)
*Survey weighted by age, sex, and residence; numbers may not add up to 100% due
to rounding.
TABLE 3. Predictors of Taking Antiretroviral treatment (ART) Among 619 Adults Eligible* by CD4+ Cell Count ,350 Cells Per
Cubic Millimeter†
Not on ART at
Follow-up,‡ N (%)
On ART at
Follow-up,‡ N (%) Total, N
Unadjusted
OR 95% CI aOR 95% CI
Total 158 (26) 461 (75) 619 —
Sex
Female 90 (23) 301 (77) 391 Ref Ref
Male 68 (30) 160 (70) 228 0.70 0.48 to 1.03 0.76 0.46 to 1.26
Age
18–24 34 (42) 47 (58) 81 Ref Ref
25–29 40 (34) 78 (66) 118 1.43 0.77 to 2.62 1.17 0.56 to 2.45
30–34 29 (22) 102 (78) 131 2.60 1.37 to 4.94 1.88 0.86 to 4.09
35–39 34 (26) 98 (75) 132 2.14 1.19 to 3.82 1.72 0.8 to 3.67
40–44 19 (20) 73 (80) 92 2.89 1.47 to 5.65 2.10 0.84 to 5.25
45–49 3 (4) 63 (96) 65 17.20 4.85 to 61.01 15.28 3.77 to 62.01
HIV aware at baseline
Unaware 85 (68) 40 (32) 125 Ref Ref
Aware 73 (15) 421 (85) 494 12.37 7.81 to 19.58 10.62 6.53 to 17.25
Visit health facility since diagnosis
No visit 72 (100) 0 (0) 72 —
Have visited health facility 86 (16) 461 (84) 547 —
Ever told by doctor to take ART
No 108 (96) 0 (0) 113 —
Yes 50 (10) 461 (91) 506
*All those reporting being “on ART” were considered as having been “eligible” (CD4 ,350 or WHO stage 3 or 4) per prevailing eligibility requirements at the time of their ART
initiation.
†Survey weighted by age, sex, and residence; number may not add up to 100% due to rounding.
‡Follow-up including CD4+ cell enumeration indicating ART eligibility (,350 cells/mL3) occurred 8–12 months after baseline survey.
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Predictors of Viral Suppression at Follow-up
8–12 Months After SHIMS Baseline Survey
Among Those Reporting ART Use at Follow-up
Among 461 participants who reported being on ART,
VL was ,1000 copies per milliliter in 394 (86%) (Table 4).
In multivariate analysis, viral suppression among those
who reported being on ART was only associated with being
older than 24 years of age but not with having already been
aware of their HIV infection or on ART at the time of the
SHIMS baseline survey nor with other demographic
variables, including sex. Those who reported not filling
their ART prescription in the previous 3 months were
significantly less likely to have suppressed VL (aOR: 0.20,
CI: 0.04 to 0.87).
DISCUSSION
In Swaziland, the country with the most severe
national HIV epidemic globally, our analysis determined
that 8–12 months after SHIMS baseline survey had diag-
nosed or reconfirmed HIV-infected status, almost all partic-
ipants not on ART had a VL$1000 copies per milliliter, and
40% of these were ART ineligible by the 2013 WHO
treatment eligibility guidelines (ie, CD4 ,500/mL). This
population of ART-ineligible adults due to high CD4 count
represents 18% of the HIV-infected population, or an
estimated 40,727 persons with a VL high enough to be
a risk factor for HIV transmission.
Swaziland has implemented a strong HIV treatment
program, as evidenced by our study finding that 74% of
those participants who were ART eligible based on the
prevailing CD4+ count threshold of ,350 cells per
microliter reported using ART, and 85% of those who
reported using ART had viral suppression. The proportion
of those eligible who had started treatment had increased
by 22% during the time between SHIMS baseline and
follow-up surveys, and 73% of those starting ART use after
SHIMS baseline had achieved viral suppression, further
demonstrating the feasibility of effective treatment pro-
grams in a low resource setting. Despite these successes,
the annual HIV incidence remains high,16 which may be
explained in part by the gap in transmission prevention
when ART initiation guidelines are based solely on CD4+
cell count.
All participants in the Swaziland analysis had docu-
mented HIV infection 8–12 months earlier, at SHIMS
baseline survey, and most, 71%, reported having already
been aware of their infection at that time. Thus, the high VL
levels documented in this survey are unlikely to be due to
recent infection.17 Our data suggest that for HIV treatment
to contribute to prevention in this high incidence setting,
eligibility criteria for initiation on ART need to be
expanded beyond CD4+ cell count cutoff to include a VL
threshold or a test-and-treat approach. Only 3% of the
adult HIV-infected population would not be eligible with
the combined criteria of CD4 count ,500 cells per
microliter and/or VL $1000 copies per milliliter, and some
would be eligible by other criteria already adopted by
Swaziland, including pregnancy, tuberculosis, or being in
a serodiscordant relationship. Thus, test-and-treat seems
the most straightforward strategy, avoiding VL measure-
ment as a potential default point during enrollment in
treatment, and in line with recent data from the TEMPRANO
and START trials demonstrating individual clinical
benefits from starting ART at CD4+ counts higher than
500 cells per microliter.2,3 Tanser et al18 have demonstrated
in routine programmatic conditions at the community level
that increased ART coverage results in population-level
reductions in risk. In Swaziland, it is clear that coverage
must extend beyond those eligible based on a CD4+
count threshold.
Challenges with starting people on ART at higher CD4+
counts, when they are generally healthy, have been poor
adherence with associated persistent viremia and outright
refusal to take ART.19–22 However, Jain et al23 have recently
demonstrated high rates of adherence, retention in care, viral
suppression, and safety when treating patients with high
CD4+ counts in Uganda [median: 569 cells/mL (interquartile
range: 451–716)]. They pointed out that patient attitudes may
be changing as they learn more about clinical benefits and
reduced transmission to others when starting ART earlier.
Just, as knowledge of HIV-infected status has been docu-
mented to reduce HIV risk-related behavior after HIV
testing,24,25 it is possible that the knowledge of high VL
status, and its associated risk for HIV transmission, may
change other behaviors such as retention in care and
adherence with treatment.
To our knowledge, this study is the first to assess
nationally representative population data to estimate the
proportion and number of the HIV-infected adult popula-
tion with high VL that would remain ineligible for ART
with expanding CD4+ count criteria. However, our study
has limitations. The association between VL and CD4+
count in untreated adults in a population will vary depend-
ing on the incidence rate in recent years, the age of the
epidemic, the predominant viral subtype, and the viral set
point in the population.26,27 Thus, the results from
Swaziland, which has a mature generalized epidemic with
one of the highest HIV incidence rates in the world, may
not apply to all settings. Additionally, we were unable to
verify ART treatment status beyond self-report for one-
third of the participants, as they did not have their ART
clinic record available at the time of interview, and we
considered all those reporting being on ART as having
been eligible per prevailing eligibility requirements at the
time of their ART initiation but did not have clinical
verification of their eligibility status at that time. We used
data from census and surveys conducted by different
methods and with different age ranges for adults to arrive
at an estimate of the size of the HIV-infected adult
population, then used those estimates to calculate estimated
numbers of adults who would be treatment eligible from the
proportions determined in our substudy. Finally, the rates
of treatment coverage and viral suppression were measured
8–12 months after home-based HIV testing or retesting
during SHIMS baseline survey and may not reflect the
general HIV-infected population in the absence of home-
based testing.
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Access to VL measurement has been limited in
resource-constrained settings because of the cost, and point-
of-care quantification technologies, although in development,
are not imminent.28,29 Determining eligibility based on VL
would require routine VL assessment, which would increase
program costs and add an additional step along the treatment
cascade, where patients could be lost to follow up. Imple-
menting a test-and-treat approach would not require VL
measurements for eligibility determination, and in Swaziland
would result in an additional 21% of the HIV-infected adult
population added to the treatment rolls, most of whom, 86%,
have VL high enough to be a risk factor for HIV transmission.
TABLE 4. Predictors of Viral Load (VL) Suppression (,1000 Copies/mL) Among 461 Adults Who Report Taking Antiretroviral





VL, N (%) Total, N
Unadjusted
OR 95% CI aOR 95% CI
Total 67 (15) 394 (86) 461 — — — —
Sex
Female 45 (15) 256 (85) 301 Ref Ref
Male 22 (14) 138 (87) 160 1.13 0.64 to 2.01 0.82 0.43 to 1.56
Age
18–24 22 (46) 25 (54) 47 Ref Ref
25–29 10 (13) 68 (87) 78 5.74 2.43 to 13.53 6.16 2.26 to 16.78
30–34 8 (8) 94 (92) 102 10.1 3.68 to 27.7 9.99 3.11 to 32.07
35–39 12 (13) 86 (87) 98 5.89 2.45 to 14.18 5.81 2.04 to 16.55
40–44 11 (15) 62 (85) 73 4.83 1.79 to 13 4.79 1.43 to 16.09
45–49 4 (6) 59 (94) 63 14.43 3.63 to 57.35 14.09 3.14 to 63.3
HIV aware at baseline
Unaware 14 (34) 26 (66) 40 Ref Ref
Aware 53 (13) 368 (87) 421 3.54 1.69 to 7.39 1.20 0.32 to 4.48
On ART at baseline
Not on ART 27 (27) 73 (73) 100 Ref Ref
On ART 40 (11) 321 (89) 361 2.96 1.71 to 5.12 1.98 0.87 to 4.5
Marital/cohabitation status
Married or cohabitating 41 (15) 238 (85) 280 Ref Ref
Not married or cohabitating 23 (13) 153 (87) 176 1.13 0.63 to 2.04 1.41 0.71 to 2.82
Missing response 2 (35) 3 (65) 5 0.32 0.05 to 2.12 0.16 0.02 to 1.44
Education
Did not attend 6 (14) 37 (86) 43 Ref Ref
Primary 28 (15) 160 (85) 187 0.93 0.37 to 2.33 1.09 0.35 to 3.38
Secondary 27 (14) 169 (86) 197 1.01 0.41 to 2.48 1.30 0.39 to 4.29
Tertiary 6 (18) 25 (82) 30 0.73 0.22 to 2.44 0.97 0.27 to 3.47
Missing response 0 (0) 3 (100) 3 Omitted Omitted
Employment
Employed (any form) 24 (12) 176 (88) 201 Ref Ref
Unemployed (incl. retired/
disabled)
41 (16) 216 (84) 257 0.72 0.43 to 1.22 0.86 0.45 to 1.67
Missing response 1 (36) 2 (64) 3 0.24 0.02 to 2.81 1.33 0.08 to 21.33
Residence
Urban 49 (15) 281 (85) 330 Ref Ref
Rural 18 (14) 113 (86) 131 1.07 0.62 to 1.85 1.23 0.56 to 2.69
Region
Hhohho 12 (11) 98 (89) 111 Ref Ref
Lubombo 16 (20) 65 (80) 82 0.50 0.26 to 0.98 0.39 0.19 to 0.82
Manzini 23 (15) 127 (85) 150 0.69 0.35 to 1.35 0.49 0.21 to 1.14
Shiselweni 15 (13) 104 (88) 119 0.88 0.43 to 1.77 0.84 0.38 to 1.84
Last refill of ART prescription
,3 mo ago 62 (14) 384 (86) 446 Ref Ref
$3 mo ago 4 (53) 3 (47) 7 0.14 0.033 to 0.61 0.20 0.04 to 0.87
Missing response 1 (12) 7 (88) 8 1.17 0.13 to 10.17 2.57 0.08 to 81.47
*Survey weighted by age, sex and residence; number may not add up to 100% due to rounding. Follow-up including VL measurement occurred 8–12 months after baseline.
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The treatment for them would provide both an individual and
public health benefit.
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